Ambroxol Hydrochloride EP 8.0 Powder

Ambroxol hydrochloride is a mucolytic and secretolytic agent used in medicinal products to help loosen thick respiratory mucus and facilitate its clearance in conditions associated with excessive or viscous bronchial secretions. The indications of a finished medicine depend on its approved formulation and local prescribing information.

Hypersensitivity to ambroxol hydrochloride or any component of the finished medicinal product. Additional contraindications depend on the formulation and its approved product information.

Possible adverse reactions include nausea, vomiting, diarrhea, abdominal discomfort, altered taste, and dry mouth. Hypersensitivity reactions, including rash, urticaria, and angioedema, may occur. Rare but serious reactions include anaphylaxis and severe cutaneous adverse reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis.

Use caution in patients with impaired mucociliary clearance, a history of peptic ulcer disease, or significant kidney or liver impairment. Discontinue treatment and seek medical assessment if a progressive skin rash, blistering, mucosal lesions, or other signs of a severe hypersensitivity reaction develop. The safety and suitability of treatment during pregnancy and breastfeeding should be assessed according to the applicable product information. Pharmaceutical powder intended for manufacturing must not be used directly as a finished medicine without appropriate formulation and quality control.

There is no patient dose for the API powder itself. For finished ambroxol medicines, dosage depends on the product strength, dosage form, age, and approved local labeling. Use only the dose specified in the prescribing information for the finished medicinal product.

Clinically significant interactions are not well established for ambroxol. Concomitant use with cough suppressants may impair the clearance of loosened respiratory secretions and should be assessed by a healthcare professional. Review the specific finished product information before combining ambroxol with other medicines.

European Pharmacopoeia, EP 8.0 monograph specifications where applicable; European Medicines Agency (EMA); national medicines regulatory authorities; official ambroxol hydrochloride product information.